Geoffrey E. Harris - 17 Jan 2023 Form 4 Insider Report for Vyant Bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jan 2023, 15:30:27 UTC
Prior SEC filing: 22 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew LaFrence, attorney-in-fact

Key filing fact

Geoffrey E. Harris filed Form 4 for Vyant Bio, Inc. on 19 Jan 2023.

Key facts

This page summarizes Geoffrey E. Harris's Form 4 filing for Vyant Bio, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Jan 2023, 15:30.

Change

Previous filing in this sequence was filed on 22 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNT transaction

Common Stock, $0.0001 par value

Award

Transaction value
Shares: +5,712
Change %: +41%
Price
Shares after: 19,761
Date: 17 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 17, 2023, the Reporting Person was granted 5,712 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date.